BR112016027674A2 - Formas melhoradas de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas - Google Patents

Formas melhoradas de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas

Info

Publication number
BR112016027674A2
BR112016027674A2 BR112016027674A BR112016027674A BR112016027674A2 BR 112016027674 A2 BR112016027674 A2 BR 112016027674A2 BR 112016027674 A BR112016027674 A BR 112016027674A BR 112016027674 A BR112016027674 A BR 112016027674A BR 112016027674 A2 BR112016027674 A2 BR 112016027674A2
Authority
BR
Brazil
Prior art keywords
pi3k delta
pharmaceutical formulations
improved forms
delta inhibitor
selective
Prior art date
Application number
BR112016027674A
Other languages
English (en)
Portuguese (pt)
Inventor
Kumar Venkata Satya Vakkalanka Swaroop
Original Assignee
Rhizen Pharmaceuticals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhizen Pharmaceuticals Sa filed Critical Rhizen Pharmaceuticals Sa
Publication of BR112016027674A2 publication Critical patent/BR112016027674A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BR112016027674A 2014-05-27 2015-05-26 Formas melhoradas de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas BR112016027674A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2596CH2014 2014-05-27
IN2597CH2014 2014-05-27
PCT/IB2015/053940 WO2015181728A1 (en) 2014-05-27 2015-05-26 Improved forms of a pi3k delta selective inhibitor for use in pharmaceutical formulations

Publications (1)

Publication Number Publication Date
BR112016027674A2 true BR112016027674A2 (pt) 2017-08-15

Family

ID=53499042

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016027674A BR112016027674A2 (pt) 2014-05-27 2015-05-26 Formas melhoradas de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas

Country Status (22)

Country Link
US (4) US9969740B2 (enExample)
EP (2) EP3149000B1 (enExample)
JP (3) JP6987501B2 (enExample)
KR (1) KR20170007480A (enExample)
CN (2) CN106661030B (enExample)
AU (1) AU2015265542B2 (enExample)
BR (1) BR112016027674A2 (enExample)
CA (1) CA2949932C (enExample)
CY (1) CY1124316T1 (enExample)
DK (1) DK3149000T3 (enExample)
EA (1) EA032506B1 (enExample)
ES (1) ES2880999T3 (enExample)
HR (1) HRP20211151T1 (enExample)
HU (1) HUE054916T2 (enExample)
IL (1) IL249058B2 (enExample)
LT (1) LT3149000T (enExample)
PL (1) PL3149000T3 (enExample)
PT (1) PT3149000T (enExample)
RS (1) RS62136B1 (enExample)
SI (1) SI3149000T1 (enExample)
SM (1) SMT202100532T1 (enExample)
WO (1) WO2015181728A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100532T1 (it) * 2014-05-27 2021-11-12 Rhizen Pharmaceuticals S A Sale tosilato cristallino di un inibitore 5 selettivo di pi3k delta per l’uso in formulazioni farmaceutiche
AU2017268839A1 (en) 2016-05-27 2018-11-29 Laboratoire Francais Du Fractionnement Et Des Biotechnologies Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat B-cell proliferative disorders
US20190247399A1 (en) 2016-09-09 2019-08-15 Tg Therapeutics, Inc. Combination of an anti-cd20 antibody, pi3 kinase-delta inhibitor, and anti-pd-1 or anti-pd-l1 antibody for treating hematological cancers
WO2021009509A1 (en) 2019-07-15 2021-01-21 Johnson Matthey Public Limited Company Amorphous umbralisib monotosylate
US20220143026A1 (en) 2020-11-12 2022-05-12 Tg Therapeutics, Inc. Triple combination to treat b-cell malignancies
US11965032B1 (en) 2022-06-01 2024-04-23 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11814439B1 (en) 2022-06-01 2023-11-14 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11884740B1 (en) 2022-06-01 2024-01-30 Tg Therapeutics, Inc. Anti-CD20 antibody compositions
US11807689B1 (en) 2022-06-01 2023-11-07 Tg Therapeutics, Inc. Anti-CD20 antibody compositions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100785363B1 (ko) * 2000-04-25 2007-12-18 이코스 코포레이션 인간 포스파티딜-이노시톨 3-키나제 델타의 억제제
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
WO2005016348A1 (en) 2003-08-14 2005-02-24 Icos Corporation Method of inhibiting immune responses stimulated by an endogenous factor
JP5794919B2 (ja) 2008-11-13 2015-10-14 ギリアード カリストガ エルエルシー 血液学的な悪性疾患のための療法
BRPI1012333A2 (pt) 2009-03-24 2016-03-29 Gilead Calistoga Llc atropisômeros de derivados de 2-purinil-3-tolil-quinazolinonas e métodos de uso
SG175259A1 (en) 2009-04-20 2011-11-28 Gilead Calistoga Llc Methods of treatment for solid tumors
LT2870157T (lt) 2012-07-04 2017-12-11 Rhizen Pharmaceuticals S.A. Selektyvieji pi3k delta inhibitoriai
SMT202100532T1 (it) * 2014-05-27 2021-11-12 Rhizen Pharmaceuticals S A Sale tosilato cristallino di un inibitore 5 selettivo di pi3k delta per l’uso in formulazioni farmaceutiche

Also Published As

Publication number Publication date
IL249058B2 (en) 2023-03-01
EP3149000A1 (en) 2017-04-05
PL3149000T3 (pl) 2021-11-02
AU2015265542B2 (en) 2019-05-09
RS62136B1 (sr) 2021-08-31
KR20170007480A (ko) 2017-01-18
AU2015265542A1 (en) 2016-12-08
US20170121336A1 (en) 2017-05-04
US20190016725A1 (en) 2019-01-17
DK3149000T3 (da) 2021-08-30
ES2880999T3 (es) 2021-11-26
JP2020122022A (ja) 2020-08-13
US9969740B2 (en) 2018-05-15
US20190382411A1 (en) 2019-12-19
CN106661030B (zh) 2020-06-30
LT3149000T (lt) 2021-09-10
HUE054916T2 (hu) 2021-10-28
US20210269446A1 (en) 2021-09-02
WO2015181728A1 (en) 2015-12-03
IL249058A0 (en) 2017-01-31
JP2017516785A (ja) 2017-06-22
IL249058B (en) 2022-11-01
JP6987501B2 (ja) 2022-01-05
EA201692255A1 (ru) 2017-04-28
CY1124316T1 (el) 2022-07-22
PT3149000T (pt) 2021-07-27
SI3149000T1 (sl) 2021-09-30
SMT202100532T1 (it) 2021-11-12
US10414773B2 (en) 2019-09-17
EP3149000B1 (en) 2021-06-30
CA2949932C (en) 2021-08-10
JP2022082680A (ja) 2022-06-02
HRP20211151T1 (hr) 2021-10-15
EA032506B1 (ru) 2019-06-28
CN111635406A (zh) 2020-09-08
CA2949932A1 (en) 2015-12-03
US10947244B2 (en) 2021-03-16
CN106661030A (zh) 2017-05-10
EP3971188A1 (en) 2022-03-23

Similar Documents

Publication Publication Date Title
BR112016027674A2 (pt) Formas melhoradas de um inibidor seletivo de pi3k delta para uso em formulações farmacêuticas
MX383164B (es) Composicion que contiene arn para tratamiento de enfermedades tumorales.
CL2017002650A1 (es) Compuestos novedosos
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
AR091677A1 (es) INHIBIDORES DE PI3K d SELECTIVOS
BR112015030385A8 (pt) composto, composto para uso e composição farmacêutica
MX2018005708A (es) Compuesto de 7-(tiazol-5-il)pirrolopirimidina como agonista de tlr7.
BR112018071585A2 (pt) formulações de um inibidor de lsd1
CL2014001547A1 (es) Compuestos derivados de benzotienilo-pirrolotriazina, como inhibidores de la proteina tirosina quinasa; procedimiento de preparacion de dichos compuestos; composicion farmaceutica que los comprende; y su uso para el tratamiento y/o la prevencion de cancer y enfermedades tumorales.
BR112015000615A8 (pt) Purinas macrocíclicas para o tratamento de infecções virais e composição farmacêutica que as compreende
BR112016011065A8 (pt) composto cristalino, composição farmacêutica, forma de dosagem, método para tratar anemia
BR112015026023A2 (pt) derivados de 2- aminopirido[4,3-d]pirimidin-5-ona e seu uso como inibidores de wee-1
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112017025781A2 (pt) derivados de 2-(pirazolopiridin-3-il)pirimidina como inibidores de jak
BR112014009006B8 (pt) Compostos heterocíclicos e métodos de uso dos mesmos
BR112017003346B8 (pt) Derivados de pirazolopiridina, seus usos, e composição farmacêutica
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
NI201600176A (es) Compuestos de 1, 3, 4 - tiadiazol y uso de los mismos para el tratamiento del cáncer.
BR112016011170A8 (pt) derivados de heteroaril ácido butanoico, seus usos, combinação e composição farmacêutica
BR112017006002A2 (pt) compostos de imidazopiridazina e seu uso
MX2021010041A (es) Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt.
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto
BR112015030774A2 (pt) novos compostos para o tratamento de câncer
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112017020818A2 (pt) composto, uso de um composto, método, e, medicamento

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.